中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2013年
11期
17-18
,共2页
杨静%张江淮%吴永贵%胡淑荣
楊靜%張江淮%吳永貴%鬍淑榮
양정%장강회%오영귀%호숙영
终末期肾病%透析%肾性骨病%鲑鱼降钙素%骨化三醇
終末期腎病%透析%腎性骨病%鮭魚降鈣素%骨化三醇
종말기신병%투석%신성골병%해어강개소%골화삼순
ESRD%renal osteodystrophy%salmon calcitonin%ossification in three alcohol
目的：观察鲑鱼降钙素联合骨化三醇治疗肾性骨病（renal osteopathy）的疗效。方法：对66例肾性骨病患者随机分为治疗组和对照组，均予以治疗基础疾病，治疗组加用鲑鱼降钙素（20 u，皮下注射，每周3次(常规血液透析时使用),同时加口服骨化三醇治疗（0.25-1.0ug/d）；对照组用鲑鱼降钙素，在治疗前及治疗3、6、12个月时分别检测血甲状旁腺激素(PTH)、血钙、血磷水平和腰椎，以及记录骨痛程度(采用视觉模拟疼痛评分，VAS)和不良反应。结果：对照组治疗前血清钙、血清磷和PTH分别2.10±0.28、2.82±0.34、868.50±125.57，治疗后分别为2.34±0.23、2.23±0.23和723.39±117.73；治疗组治疗前甲状旁腺激素(PTH)、血钙、血磷水平2.15±0.40、2.78±0.45、891.45±124.73，治疗后分别为2.78±0.46、2.12±0.21、610.57±124.12，治疗前后比较差异有统计学意义（p＜0.05），治疗组改善更为明显（P<0.05）。结论：在肾性骨病患者中应用鲑鱼降钙素及合用骨化三醇可有效减少MHD患者的骨量丢失，降低PTH水平，改善临床症状，且无明显不良反应。值得临床推广应用。
目的：觀察鮭魚降鈣素聯閤骨化三醇治療腎性骨病（renal osteopathy）的療效。方法：對66例腎性骨病患者隨機分為治療組和對照組，均予以治療基礎疾病，治療組加用鮭魚降鈣素（20 u，皮下註射，每週3次(常規血液透析時使用),同時加口服骨化三醇治療（0.25-1.0ug/d）；對照組用鮭魚降鈣素，在治療前及治療3、6、12箇月時分彆檢測血甲狀徬腺激素(PTH)、血鈣、血燐水平和腰椎，以及記錄骨痛程度(採用視覺模擬疼痛評分，VAS)和不良反應。結果：對照組治療前血清鈣、血清燐和PTH分彆2.10±0.28、2.82±0.34、868.50±125.57，治療後分彆為2.34±0.23、2.23±0.23和723.39±117.73；治療組治療前甲狀徬腺激素(PTH)、血鈣、血燐水平2.15±0.40、2.78±0.45、891.45±124.73，治療後分彆為2.78±0.46、2.12±0.21、610.57±124.12，治療前後比較差異有統計學意義（p＜0.05），治療組改善更為明顯（P<0.05）。結論：在腎性骨病患者中應用鮭魚降鈣素及閤用骨化三醇可有效減少MHD患者的骨量丟失，降低PTH水平，改善臨床癥狀，且無明顯不良反應。值得臨床推廣應用。
목적：관찰해어강개소연합골화삼순치료신성골병（renal osteopathy）적료효。방법：대66례신성골병환자수궤분위치료조화대조조，균여이치료기출질병，치료조가용해어강개소（20 u，피하주사，매주3차(상규혈액투석시사용),동시가구복골화삼순치료（0.25-1.0ug/d）；대조조용해어강개소，재치료전급치료3、6、12개월시분별검측혈갑상방선격소(PTH)、혈개、혈린수평화요추，이급기록골통정도(채용시각모의동통평분，VAS)화불량반응。결과：대조조치료전혈청개、혈청린화PTH분별2.10±0.28、2.82±0.34、868.50±125.57，치료후분별위2.34±0.23、2.23±0.23화723.39±117.73；치료조치료전갑상방선격소(PTH)、혈개、혈린수평2.15±0.40、2.78±0.45、891.45±124.73，치료후분별위2.78±0.46、2.12±0.21、610.57±124.12，치료전후비교차이유통계학의의（p＜0.05），치료조개선경위명현（P<0.05）。결론：재신성골병환자중응용해어강개소급합용골화삼순가유효감소MHD환자적골량주실，강저PTH수평，개선림상증상，차무명현불량반응。치득림상추엄응용。
Objective:To observe the effects of salmon calcitonin combined ossification in three alcohol for treatment of renal osteodystrophy (renal osteopathy) effect. Methods:66 cases of patients with renal osteodystrophy were randomly divided into treatment group and control group, were treated with the basis of disease treatment, the treatment group added with salmon calcitonin (3 times 20 u, subcutaneous injection, once a week (with conventional hemodialysis), at the same time plus oral ossification in three alcohol treatment (0.25-1.0ug/D);control group with salmon calcitonin, parathyroid hormone in blood were detected before treatment and 3, 6, and 12 months (PTH), serum calcium, serum phosphorus level and lumbar pain, and the record level (visual analogue scale, VAS) and adverse reaction. Results:in the control group before treatment, serum calcium, serum phosphorus and PTH were 2.10 ± 0.28, 2.82 ± 0.34, 868.50 ± 125.57, after treatment were 2.34 ± 0.23, 2.23 ± 0.23 and 723.39 ± 117.73;the treatment group before treatment of parathyroid hormone (PTH), serum calcium, serum phosphorus level of 2.15 ± 0.40, 2.78 ± 0.45 、891.45 ± 124.73, after treatment were 2.78 ± 0.46, 2.12 ± 0.21, 610.57 ± 124.12, before and after the treatment, the difference was statistical y significant (P<0.05), the treatment group improved more obviously (P<0.05). Conclusion:the application of salmon calcitonin and combined with ossification in three alcohol can effectively reduce MHD in patients with bone loss in patients with renal osteodystrophy, decrease the level of PTH, improve the clinical symptomsand no obvious adverse reaction. It is worthy of clinical application.
